The production of antibodies for research and therapeutic purposes is a sophisticated field that combines biotechnology, immunology, and genetic engineering. This arena has seen remarkable advancements, shaping how diseases are treated and understood. Here are ten fascinating facts about this cutting-edge field.
Scientists can create antibodies tailored to recognize specific proteins, pathogens, or cells. This process involves immunizing animals with an antigen to elicit an immune response, then harvesting and purifying the antibodies produced. These custom antibodies are critical for research, diagnostics, and therapy.
In therapeutic and research contexts, antibodies are classified into monoclonal and polyclonal based on their production methods and specificity. Monoclonal antibodies are derived from a single B cell clone and recognize one epitope, while polyclonal antibodies are sourced from multiple B cell clones, recognizing multiple epitopes on an antigen, offering a broader response.
The creation of monoclonal antibodies revolutionized by the development of hybridoma technology in 1975. This method involves fusing an antibody-producing B cell with a myeloma (cancer) cell, creating a hybrid cell (hybridoma) that can both produce the desired antibody and proliferate indefinitely in culture.
Advancements in genetic engineering have enabled the production of recombinant antibodies, which are produced by inserting the gene sequences encoding the antibody into bacterial, yeast, or mammalian cells. This method offers improved consistency, scalability, and the ability to modify the antibodies for enhanced efficacy or reduced immunogenicity.
For applications requiring large scale antibody production, recombinant technologies provide an efficient and reliable solution, ensuring high-quality antibodies are delivered to meet therapeutic, research, and diagnostic demands.
ADCs represent a breakthrough in targeted cancer therapy. These are monoclonal antibodies linked to a drug or radioactive compound. The antibody binds to specific targets on cancer cells, delivering the therapeutic agent directly to the tumor, minimizing damage to healthy cells.
Bispecific antibodies are engineered to recognize two different antigens or epitopes simultaneously. This capability makes them particularly useful in cancer therapy, where one part of the antibody can target a tumor cell, and the other can recruit and activate immune cells to destroy the tumor.
Phage display technology is a method used to discover novel antibodies and engineer their properties. It involves displaying antibody fragments on the surface of bacteriophages (viruses that infect bacteria) and screening them against antigens to identify high-affinity binders.
To reduce the risk of immune reactions, researchers have developed humanized and fully human antibodies for therapeutic use. Humanized antibodies are derived from non-human species but have been modified to resemble human antibodies closely. Fully human antibodies are produced using transgenic mice or phage display libraries, completely bypassing the need for non-human antibodies.
Cryo-electron microscopy (Cryo-EM) has become a crucial tool in antibody research, allowing scientists to visualize antibodies bound to their antigens at near-atomic resolution. This technique helps in understanding how antibodies neutralize pathogens and assists in the design of vaccines and therapeutics.
Beyond therapeutics, antibodies play a vital role in diagnostics. They are used in tests such as ELISA, rapid antigen tests, and immunohistochemistry to detect the presence of pathogens, proteins, or biomarkers in samples. The specificity and sensitivity of antibodies make them invaluable in these applications.
As of the end of 2025, 21 ADCs have been approved globally, with four new approv……
Antibody engineering has progressed beyond classical depletion and neutralizatio……
The 2025 Antibody Engineering & Therapeutics US (AET US) conference was held in ……
The 2025 mAbTalk Symposium by The Chinese Antibody Society was held in San Deigo……
You can also contact us on the Scientist and Science Exchange marketplaces.
